产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
XMD17-109 is a cell-permeable, non-cytotoxic ATP site-targeting pyrimido-diazepinone derivative that acts as potent inhibitor against ERK5 (MAPK7, BMK1) kinase activity in cell-free assay (IC50 = 162 nM; [ATP] = 50 μM) and EGF-induced ERK5 autophosphorylation in HeLa cells (IC50 = 90 nM). XMD17-109 displayed excellent target selectivity on a 442-kinase panel. XMD17-109 effectively inhibits inflammatory stimuli-induced IL-6 and IL-8 production from human endothelial cells in vitro and protects mice from LPS-induced mortality and systemic inflammation & coagulopathy in vivo with good pharmacokinetics.
基本信息
经验(实验)分子式 | C36H46N8O3 |
分子量 | 638.80 |
NACRES | NA.77 |
产品性质
质量水平 | 100 |
测定 | ≥98% (HPLC) |
形式 | powder |
颜色 | white to beige |
溶解性 | DMSO: 20 mg/mL, clear |
储存温度 | −20℃ |
安全信息
象形图 | |
警示用语: | Warning |
危险声明 | H315 - H319 |
预防措施声明 | P305 + P351 + P338 |
危险分类 | Eye Irrit. 2 - Skin Irrit. 2 |
储存分类代码 | 13 - Non Combustible Solids |
WGK | WGK 3 |
闪点(F) | Not applicable |
闪点(C) | Not applicable |